A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2019
Price : $35 *
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- Acronyms NICCI
- 16 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 20 Mar 2019 Planned number of patients changed from 75 to 40.
- 20 Mar 2019 Planned End Date changed from 1 Mar 2020 to 1 Dec 2020.